17a-Estradiol

From NuGOwiki

(Redirected from HMDB00429)

The NuGOwiki Metabolite Database is a joint initiative of NuGO and HMDB

Taxonomy Navigation Box; search by

17a-Estradiol
2D structure for 17a-Estradiol
Chemical Name	(8S,9S,13S,14S,17R)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta
Chemical Formula	C₁₈H₂₄O₂
CAS Number	57-91-0
Chemical Information	HMDB00429
Biochemical Taxonomy	Steroids and Steroid Derivatives
Functional Taxonomy	Not Available
Nutritional Taxonomy	Not Available
Metabolic Pathways	Androgen and Estrogen Metabolism Glutathione Metabolism Pentose and Glucuronate Interconversions Porphyrin and Chlorophyll Metabolism Starch and Sucrose Metabolism
Biofluid Location	Blood Urine
Tissue Location	Not Available
Normal Biofluid Concentrations	Blood: 0.32 +/- 0.0001 umol/L Urine: 0.00262+/-0.00065 umol/mmol creatinine Urine: 2.3 +/- 1.6 umol/mmol creatinine
Normal Tissue Concentrations	Not Available
Diseases / Conditions Related to Nutrition	glutaryl-CoA dehydrogenase deficiency (GDHD),
Other (Monogenic Disorders)	Not Available
Abnormal Biofluid Concentrations	Urine (glutaryl-CoA dehydrogenase deficiency (GDHD),): 9.4 +/- 5.0 umol/mmol creatinine
Abnormal Tissue Concentrations	Not Available
Physiological Processes	Not Available

Authors:
Affiliations:

Introduction

guidelines
17a-estradiol is found in the estrogen patch. The estrogen patch is a delivery system for estradiol used as hormone replacement therapy to treat the symptoms of menopause, such as hot flashes and vaginal dryness, and to prevent osteoporosis. Originally marketed as Vivelle (Novartis), it was discontinued in 2003 and reintroduced in a smaller form as Vivelle-Dot. Although the estrogen is given transdermally rather than in the standard oral tablets, the estrogen patch carries similar risks and benefits as more conventional forms of estrogen-only hormone replacement therapy.